ever, found no association between 9q LOH and UV radiation exposure, as assessed by site or UV radiation-related mutations in p53.
Gailani et al. (3) concluded, ''BCC incidence may reflect an etiologic contribution of additional environmental agents'' acting synergistically with UVB radiation. Suggested agents included arsenicals, polycyclic aromatic hydrocarbons (PAHs), ionizing radiation, and/or UVA radiation. We have obtained molecular epidemiologic data that support this conclusion.
Ionizing radiation and arsenic are BCC risk factors (5), possibly via reactive oxygen species (ROS)-mediated mechanisms. While various enzymes detoxify ROS and their oxidation products, much data indicate the importance of the glutathione S-transferase (GST) supergene family (6). Various environmental, carcinogenic nitrosamines and PAHs are metabolized by enzymes of the cytochrome P450 (CYP) supergene family (6). We have examined the hypothesis that effectiveness in detoxifying the products of ROS action and environmental carcinogens is significant in determining susceptibility to various cancers, including BCC. Thus, we identified associations between GSTM1, GSTM3, GSTT1, and CYP2D6 polymorphisms and susceptibility to BCC, assessed by use of tumor numbers, accrual, and site as end points (7-9). Homozygosity for the GSTM1*0 allele in combination with skin type 1 (individuals who always demonstrate an inflammatory response with burning but without tanning on exposure to UV radiation) predisposes to multiple tumors; these patients have been reported to develop an average of 4.6 tumors compared with 2.0 tumors in those without this combination (8,9). GSTT1 null is associated with faster tumor appearance (8). Similarly, the CYP2D6 EM (extensive metabolizer) genotype predisposes to multiple tumors and faster accrual. Furthermore, in individuals with a truncal tumor, an area generally not heavily exposed to UV radiation, these polymorphisms are associated with a reduced time to development of further BCCs; GSTM1-null subjects have a median time to next tumor presentation of 1.6 years compared with 5.0 years in patients with other sitegenotype combinations (P ‫ס‬ .0009; Fig. 1 ).
Our observations suggest the importance of host response to agents other than just UVB radiation. They indicate that the GSTM1 and GSTT1 enzymes detoxify products of oxidative damage and that polymorphisms in their genes influence the effectiveness of these reactions. The finding that CYP2D6 mediates susceptibility was less expected inasmuch as no link between BCC risk and exposure to environmental pollutants has been identified. Since CYP2D6 has not been detected in skin (6), we have suggested a role for hepatic detoxification of unknown carcinogens (8). The importance of UV radiation in less exposed areas such as the trunk is unclear, although, in genetically susceptible individuals, even intermittent exposure may be sufficient to promote tumorigenesis (7). 
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Paradoxical Effect of Cytotoxic Chemotherapy on Anemia in Cancer Patients With ␤-Thalassemia Minor
Thalassemia syndromes (e.g., ␣-, ␤-, ␦-, ␦␤-thalassemia) are inherited anemias characterized by reduced or absent production of one or more globin chains (␣, ␤, ␥, ␦). In ␤-thalassemia, the reduction in ␤-chain production causes an excess of ␣ chains, which are unstable and precipitate in red blood cell (RBC) precursors leading to both ineffective erythropoiesis and reduced RBC survival. ␤-Thalassemia minor is characterized by mild or minimal anemia, which, however, in some circumstances, such as during pregnancy, may become more severe and require transfusions.
Cytotoxic chemotherapy, leading to myelosuppression, would be expected to worsen the anemia of patients with ␤-thalassemia minor, thus inducing the choice of less myelotoxic regimens or prompting early transfusion practice, mainly in patients with low baseline hemoglobin (Hb) values. We evaluated the effect of chemotherapy on the anemia in breast cancer patients with ␤-thalassemia; these patients were undergoing chemotherapy as adjuvant treatment.
From November 1992 through December 1995, 245 patients with stage II breast cancer (1) were randomly assigned to receive six cycles of CEF21 (i.e., cyclophosphamide at a dose of 600 mg/m 2 , epirubicin at 60 mg/m 2 , and fluorouracil at 600 mg/m 2 intravenously on day 1) given every 21 days or the same treatment given every 14 days (CEF14) with the support of granulocyte colonystimulating factor (2) . Four of these 245 patients had a diagnosis of ␤-thalassemia (Hb A 2 level >2.5%). Two patients (ն1 and ն2) received CEF21, and two patients (ն3 and ն4) received CEF14. As a control group, a sample of 80 patients (40 treated with CEF21 and 40 treated with CEF14) was randomly extracted from the 241 patients without ␤-thalassemia.
The mean ± standard deviation of the Hb decrease (differences between the sixth and the first cycle) was significantly greater in control patients (−1.9 ± 1.09 g/dL) than in patients with ␤-thalassemia (−0.02 ± 1.13 g/dL) (P ‫ס‬ .001, Student's t test) ( Table 1) . Two ␤-thalassemic patients (ն1 and ն2) even showed an increase in Hb values, but no patient in the control group showed such an increase. The hypothesis that the patterns of Hb values among the two groups were different was tested by the analysis of variance for repeated measures, after adjustment for baseline Hb values. The interaction between the two groups and Hb values during the chemotherapy was significant (P<.001), indicating that the patterns of modification in Hb levels throughout the five chemotherapy cycles are different between ␤-thalassemic patients and control patients. Moreover, two patients in the control group and none in the ␤-thalassemic group needed RBC transfusions.
Although surprising, the paradoxical effect of chemotherapy on Hb levels in patients with ␤-thalassemia is not unexplainable. Some cytotoxic drugs, e.g., hydroxyurea, can induce an increase in the ␥ chain and thus in the hemoglobin F (HbF) level in both normal individuals and patients with ␤-thalassemia (3-5). In 
